Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02886065 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Sep 15, 2026 → Feb 15, 2027
See other at-risk trials from Massachusetts General Hospital

Record History

  1. Primary and study completion pushed from Sep 15, 2026 to Feb 15, 2027 Eligibility criteria expanded, about 4 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 4 words
  2. Primary completion date: Sep 15, 2025 to Sep 15, 2026v11
  3. Primary completion date: Sep 15, 2024 to Sep 15, 2025 Completion date: Sep 15, 2024 to Sep 15, 2026 · Study sites revised (6)v10 Show 2 more changesShow less
    • Completion date: Sep 15, 2024 to Sep 15, 2026
    • Study sites revised (6)

    See this version in full on ClinicalTrials.gov ↗

  4. Primary and study completion dates: Jun 2023 to Sep 15, 2024v9
  5. Primary and study completion dates: May 2022 to Jun 2023 Start date: Nov 2016 to Mar 7, 2017 · Trial status: Recruiting to Active, Not Recruiting · Enrollment target: estimated 20 to confirmed 19 · 1 morev8 Show 4 more changesShow less
    • Start date: Nov 2016 to Mar 7, 2017
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 20 to confirmed 19
    • Study sites: 5 to 6
Show 6 earlier versionsHide 6 earlier versions
  1. Primary and study completion dates: May 2021 to May 2022 Study sites: 4 to 5v7 Show 1 more changeShow less
    • Study sites: 4 to 5
  2. Study sites: 3 to 4v6
  3. Trial status: Active, Not Recruiting to Recruiting Study sites: 1 to 3v5 Show 1 more changeShow less
    • Study sites: 1 to 3
  4. Primary completion date: Sep 2019 to May 2021 Primary endpoint revised · Enrollment target: 26 to 20 · Completion date: Sep 2021 to May 2021 · 6 morev4 Show 9 more changesShow less
    • Primary endpoint revised
    • Enrollment target: 26 to 20
    • Completion date: Sep 2021 to May 2021
    • Interventions: Durvalumab (Drug), Hiltonol (Drug), Lenalidomide (Drug), PVX-410 (Biological) to Citarinostat (Drug), Hiltonol (Drug), Lenalidomide (Drug), PVX-410 (Biological)
    • Eligibility criteria shortened, about 37 words
    • Secondary endpoints: 4 to 5
    • Study description expanded, about 52 words
    • Study title revised
    • Study arms: 3 to 2

    See this version in full on ClinicalTrials.gov ↗

  5. Trial status: Recruiting to Active, Not Recruiting Site details revisedv3 Show 1 more changeShow less
    • Site details revised
  6. Trial status: Not Yet Recruiting to Recruiting Start date: Sep 2016 to Nov 2016 · Site details revised · Study title shortened, about 9 wordsv2 Show 3 more changesShow less
    • Start date: Sep 2016 to Nov 2016
    • Site details revised
    • Study title shortened, about 9 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This research study is studying a targeted therapy as a possible treatment for Smoldering Multiple Myeloma. The following intervention will be involved in this study: * Lenalidomide * Citarinostat (CC-96241) * PVX-410
Trial Details
NCT Number NCT02886065
Lead Sponsor Massachusetts General Hospital
Collaborators: Celgene, OncoPep, Inc.
Conditions Smoldering Multiple Myeloma
Enrollment 19 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov